Middel PFS var 4, 8 måneder for ALIMTA plus cisplatin mod 5, 1 måneder for gemcitabin plus cisplatin (justeret hazard ratio 1. 04; 95% CI 0, 94- 1, 15) og det totale respons var 30, 6% (95% CI 27, 3 - 33, 9) for Alimta plus cisplatin mod 28, 2% (95% CI 25, 0- 31, 4) for gemcitabin plus cisplatin.
Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for ALIMTA plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI 0.94-1.15), and overall response rate was 30.6% (95% CI 27.3- 33.9) for ALIMTA plus cisplatin versus 28.2% (95% CI 25.0-31.4) for gemcitabine plus cisplatin.